Elliot Kurban, MD
Cardiovascular Disease · Jackson, TNNPI 1679511026
Payments from drug & device makers
Across 402 payments — averaging $247.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$55K
- Novartis$14K
- AstraZeneca$12K
- Merck$6K
- Boston Scientific$4K
- Medtronic$2K
- plus $7K from 28 others
What the payments were for
- Travel & lodging$2,8134%
- Food & beverage$9,86515%
- Education$710%
- Other$55,25081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 3 | $55,250 |
| Novartis | 86 | $14,110 |
| AstraZeneca | 17 | $11,841 |
| Merck | 3 | $6,100 |
| Boston Scientific | 52 | $3,544 |
| Medtronic(2 entities) | 25 | $2,125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 63 | $1,177 |
| Sanofi Pasteur Inc. | 1 | $794 |
| E.r. Squibb & Sons, L.L.C. | 44 | $779 |
| Johnson & Johnson | 34 | $653 |
| Artivion, Inc. | 1 | $553 |
| Amgen | 16 | $484 |
| Cvrx, Inc. | 4 | $379 |
| Abiomed | 6 | $301 |
| Pfizer | 9 | $215 |
| Penumbra, Inc. | 2 | $187 |
| Abbott | 4 | $171 |
| Impulse Dynamics (USA) Inc. | 4 | $158 |
| Astellas Pharma US Inc | 1 | $115 |
| Edwards Lifesciences | 1 | $114 |
| Philips North America LLC | 3 | $88 |
| Baxter Healthcare | 3 | $58 |
| Intact Vascular, Inc. | 2 | $56 |
| Amarin Pharma, Inc. | 3 | $50 |
| Bayer | 2 | $49 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Bard Peripheral Vascular, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $32 |
| Reflow Medical Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| GSK | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$55,250
- CoreValve Evolut$1,335
- VersaCross Access Solution$1,064
- On-X$553
- Barostim Neo System$342
- AVVIGO Guidance System$278
- GENERAL - STENTS$237
- OPTIMIZER$206
- ROTAPRO$150
- Indigo System$149
- COMET$132
- COREVALVE EVOLUT R$132
- Impella$128
- ONYX FRONTIER$128
- CAMZYOS$127
- SYNERGY$125
- FARXIGA$125
- LEXISCAN$115
- Mitra Clip system$114
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$114
How this compares
$99,566 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 743 | $524,533 |
| XareltoRivaroxaban | 313 | $223,679 |
| EntrestoSacubitril/Valsartan | 128 | $90,415 |
| FarxigaDapagliflozin Propanediol | 100 | $69,249 |
| OzempicSemaglutide | 58 | $62,101 |
| Repatha SureclickEvolocumab | 86 | $61,659 |
| BrilintaTicagrelor | 107 | $56,136 |
| JardianceEmpagliflozin | 37 | $24,938 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,171 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $13,521 |
| VascepaIcosapent Ethyl | 35 | $13,006 |
| Ranolazine ErRanolazine | 173 | $11,515 |
| Midodrine Hcl | 124 | $10,211 |
| Praluent PenAlirocumab | 16 | $8,870 |
| Repatha SyringeEvolocumab | 13 | $6,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $215 | $524,533743 claims |
| Johnson & JohnsonXarelto | $653 | $223,679313 claims |
| AstraZenecaFarxiga, Brilinta | $11,841 | $125,386207 claims |
| NovartisEntresto | $14,110 | $90,415128 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $15 | $29,69251 claims |
| Boehringer IngelheimJardiance | $32 | $24,93837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Jackson
- Mohsin AlhaddadJackson$1.8M
- James CrenshawJackson$791K
- Christopher CherryJackson$517K
- Michael OsayamenJackson$280K
- Shahzad ShahJackson$255K
- Adeyinka AgbetoyinJackson$112K
- Brian LindmanNashville$5.5M
- David MetzgerKingsport$4.8M
- Christopher EllisNashville$4.1M
- Dinesh GuptaNashville$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.